Cargando…
Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG
BACKGROUND: Presently melanoma still lacks adequate treatment options for metastatic disease. While melanoma is exceptionally challenging to standard regimens, it is suited for treatment with immunotherapy based on its immunogenicity. Since treatment-related skin depigmentation is considered a favou...
Autores principales: | van den Boorn, Jasper G., Konijnenberg, Debby, Tjin, Esther P. M., Picavet, Daisy I., Meeuwenoord, Nico J., Filippov, Dmitri V., van der Veen, J. P. Wietze, Bos, Jan D., Melief, Cornelis J. M., Luiten, Rosalie M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869359/ https://www.ncbi.nlm.nih.gov/pubmed/20498710 http://dx.doi.org/10.1371/journal.pone.0010626 |
Ejemplares similares
-
Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial
por: Teulings, Hansje-Eva, et al.
Publicado: (2018) -
Optimization of Monobenzone-Induced Vitiligo Mouse Model by the Addition of Chronic Stress
por: Dong, Jing, et al.
Publicado: (2023) -
Depigmenting Effect of Catechins
por: Sato, Kazuomi, et al.
Publicado: (2009) -
Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients
por: Tjin, Esther P M, et al.
Publicado: (2014) -
Depigmented patches in a child
por: Leszczynska, Maria, et al.
Publicado: (2021)